Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.63 |
| ▸ | PPARD | Q03181 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 4/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496717 | 0.89 | FFAR4 (0.59) | PTPN1PPARDPPARGMAOBFFAR1 | |
| SCHEMBL18985160 | 0.89 | FFAR4 (0.59) | PTPN1PPARDPPARGMAOBFFAR1 | |
| SCHEMBL8896538 | 0.89 | PTPN1 (0.63) | PTPN1MAOBCASP3SENP8SENP7 | |
| SCHEMBL4363943 | 0.87 | MAOB (0.57) | PTPN1MAOBCASP3SENP8SENP7 | |
| SCHEMBL8000403 | 0.87 | MAOB (0.57) | PTPN1MAOBCASP3SENP8SENP7 | |
| SCHEMBL8809211 | 0.85 | MAOB (0.54) | PTPN1MAOBMRGPRX4 | |
| SCHEMBL4840332 | 0.84 | FFAR1 (0.55) | PTPN1PPARDMAOBFFAR1MRGPRX4 | |
| SCHEMBL12987826 | 0.84 | MAOB (0.55) | PTPN1MAOBS1PR1S1PR5MRGPRX4 | |
| SCHEMBL6195352 | 0.84 | MAOB (0.55) | PTPN1MAOBMRGPRX4ALDH1A1SMN1; SMN2 | |
| SCHEMBL19712578 | 0.84 | MAOB (0.55) | PTPN1MAOBALDH1A1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351737-B2 | 4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | ALLERGAN, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1485368-A1 | SUBSTITUTED CHROMAN DERIVATIVES HAVING CYTOCHROME P450RAI INHIBITORY ACTIVITY | Allergan, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6740676-B2 | TREATING DISEASES CONTROLLED BY OR RESPONSIVE TO RETINOIC ACID | ALLERGAN, INC. | 2004-05-25 | — | — | US | disclosed |
| US-20040077721-A1 | Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A | ALLERGAN, INC. | 2004-04-22 | — | — | US | disclosed |
| US-20030207937-A1 | 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | ALLERGAN, INC. | 2003-11-06 | — | — | US | disclosed |
| US-20030191181-A1 | 4-[(8-Ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome P450RAI inhibitory activity | ALLERGAN, INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2003080594-A1 | SUBSTITUTED CHROMAN DERIVATIVES HAVING CYTOCHROME P450RAI INHIBITORY ACTIVITY | ALLERGAN, INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| EP-1027332-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999018074-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Britol-Myers Squibb Pharma Company (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191181-A1 | 4-[(8-Ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome P450RAI inhibitory activity | RXRA, RARA, CYP26A1 | PTPN1 1869/4885PPARD 295/4885PPARG 124/4885 |
| US-20040077721-A1 | Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A | RARA, CYP2R1, RXRA | PTPN1 3062/4885PPARD 902/4885PPARG 141/4885 |
| US-20030207937-A1 | 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | RXRA, RARA, CYP26A1 | PTPN1 1374/4885PPARD 109/4885PPARG 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.